


HEALTH SERVICES 2023



BioNexus Gene Lab Corp Rank 16 of 91





HEALTH SERVICES 2023



BioNexus Gene Lab Corp Rank 16 of 91



The relative strengths and weaknesses of BioNexus Gene Lab Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioNexus Gene Lab Corp compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 114% points. The greatest weakness of BioNexus Gene Lab Corp is the variable Cost of Goods and Services Sold, reducing the Economic Capital Ratio by 182% points.

The company's Economic Capital Ratio, given in the ranking table, is 195%, being 182% points above the market average of 12%.

Input Variable	Value in 1000 USD
Assets, Current	6,022
Assets, Non-Current	2,718
Cost of Goods and Services Sold	9,670
Depreciation, Depletion, Amortization	0
General and Administrative Expense	1,729
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	2,035
Long Term Liabilities	71
Operating Costs and Expenses	0
Other Assets	-1,512
Other Compr. Net Income	-309
Other Expenses	-52
Other Liabilities	-31
Other Net Income	-12
Other Revenues	11,108
Property Plant and Equipment	1,512
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	8,740
Liabilities	2,075
Expenses	11,347
Revenues	11,108
Stockholders Equity	6,665
Net Income	-251
Comprehensive Net Income	-560
Economic Capital Ratio	195%

